SavedAdd your journal

Journals / Toraks Dergisi / 2006 / Cilt: 7 - Sayı: 3

Diagnostic value of early reversibility test

Erken reverzibilite testinin tanısal değeri

Tanseli GÖNLÜGÜR
Uğur GÖNLÜGÜR
Pages
178–182
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusions, acute bronchodilator response has a limited value in differentiating bronchial asthma from COPD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In the early reversibility test, spirometry is repeated to assess the bronchodilatation following the administration of an aerosol bronchodilator.
📊
Key Findings & Data:Forced vital capacity (FVC) and forced expiratory volume in 1st second (FEV1) before and 20 minutes after inhalation of 200 microgram salbutamol were retrospectively analyzed in patients of asthma (n=65) and COPD (n=71).
💡
Conclusion & Impact:In conclusions, acute bronchodilator response has a limited value in differentiating bronchial asthma from COPD.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Astım · Spirometri · Tanı

Abstract

In the early reversibility test, spirometry is repeated to assess the bronchodilatation following the administration of an aerosol bronchodilator. It is unique spirometric test for the differential diagnosis between asthma and chronic obstructive pulmonary disease (COPD). Forced vital capacity (FVC) and forced expiratory volume in 1st second (FEV1) before and 20 minutes after inhalation of 200 microgram salbutamol were retrospectively analyzed in patients of asthma (n=65) and COPD (n=71). FVC-related parameters had no a significant effects in the differential diagnosis. No significant correlations were observed between the increase in FEV1 and age or smoking history. The best parameter in the differential diagnosis of asthma and COPD was the percentage of the increase in FEV1 / predicted FEV1, and with a cut-off level for 6.5 %, the sensitivity and the specificity were only 81 %, and 86 %, respectively. In conclusions, acute bronchodilator response has a limited value in differentiating bronchial asthma from COPD.

Özet

Erken reverzibilite testinde, bir aerosol bronkodilatör uygulamasını takiben bronkodilatasyonu değerlendirmek için spirometri tekrarlanmaktadır. Test, astım ve kronik obstrüktif akciğer hastalığının (KOAH) ayırıcı tanısında kullanılan tek spirometrik testtir. 65 astım ve 71 KOAH hastasının 200 mikrogram salbutamol inhalasyonu öncesi ve 20 dakika sonrasındaki zorlu vital kapasite (FVC) ve birinci saniyedeki zorlu ekspiryum hacimleri (FEV1) retrospektif olarak araştırıldı. FVC ile ilişkili parametrelerin ayırıcı tanıda anlamlı bir değeri yoktu. FEV1'deki artışlar ile yaş veya sigara anamnezi arasında anlamlı korelasyon yoktu. Ayırıcı tanıda en iyi parametre FEV1'deki artış / beklenen FEV1 oranının yüzdesiydi ancak % 6.5 eşiğinin duyarlılığı ve özgüllüğü, sırasıyla % 81 ve % 86 idi. Sonuç olarak akut bronkodilatör cevabın astım ve KOAH'ın ayrımında sınırlı bir değeri vardır.

🔖

Cite This Article

GÖNLÜGÜR, T., GÖNLÜGÜR, U. (2006). Diagnostic value of early reversibility test. Toraks Dergisi, Cilt: 7 - Sayı: 3, 178–182. https://ajindex.com/articles/368156

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Nisar M, Walshaw M, Earis JE et al. Assessment of reversibility of airway obstruction in patients with chronic obstructive airways disease. Th orax 1990;45:190-4
  2. Meslier N, Racineux JL, Six P, Lockhart A. Diagnostic value of reversibility of chronic airway obstruction to separate asthma from chronic bronchitis: a statistical approach. Eur Respir J 1989;2:497- 505
  3. Vathenen AS, Britton JR, Ebden P et al. High-dose inhaled albuterol in severe chronic airfl ow limitation. Am Rev Respir Dis 1988;138:850-5
  4. Teale C, Morrison JF, Page RL, Pearson SB. Dose response to inhaled salbutamol in chronic obstructive airways disease. Postgrad Med J 1991;67:754-6
  5. Wempe JB, Postma DS, Breederveld N et al. Eff ects of corticosteroids on bronchodilator action in chronic obstructive lung disease. Th orax 1992;47:616-21
  6. Hay JG, Stone P, Carter J et al. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 1992;5:659-64
  7. Newnham DM, Dhillon DP, Winter JH et al. Bronchodilator reversibility to low and high doses of terbutaline and ipratropium bromide in patients with chronic obstructive pulmonary disease. Th orax 1993;48:1151-5
  8. Ullah MI, Newman GB, Saunders KB. Infl uence of age on response to ipratropium and salbutamol in asthma. Th orax 1981;36:523-9
  9. Perng DW, Huang HY, Chen HM et al. Characteristics of airway infl ammation and bronchodilator reversibility in COPD: A potential guide to treatment. Chest 2004;126:375-81
  10. Brand PL, Quanjer PH, Postma DS et al. Interpretation of bronchodilator response in patients with obstructive airways disease. Th e Dutch Chronic Non-Spesifi c Lung Disease (CNSLD) Study Group. Th orax 1992;47:429-36
  11. Toraks Derneği. Kronik obstrüktif akciğer hastalığı tanı ve tedavi rehberi. Toraks Dergisi. 2000;1 (Ek 2):1-25
  12. Anthonisen NR, Wright EC, IPPB Trial Group. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;133:814-9
  13. Th omas P, Pugsley JA, Stewart JH. Th eophylline and salbutamol improve pulmonary function in patients with irreversible chronic obstructive pulmonary disease. Chest 1992;101:160-5
  14. American Th oracic Society. ATS standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1994;152:1107-36
  15. Pare PD, Lawson LM, Brooks LA. Patterns of response to inhaled bronchodilators in asthmatics. Am Rev Respir Dis 1983;127:680-5
  16. Tashkin DP, Trevor E, Chopra SK, Tap